bioRxivGeneticsPreprint
A Dual-Locus-Targeting Strategy to Enhance CRISPR/Cas9-mediated CFTR Replacement via Helper-Dependent Adenoviral vector in porcine genome
Z Chen, Zhichang Peter ZhouiD, Rongqi Cathleen DuaniD, Amy P. WongiD, Hartmut GrasemanniD, Christine Bear, Jim HuiD
Abstract
Gene therapy has been the subject of extensive research following the advent of gene-editing technologies. Genetic disorders with difficult-to-target tissues, such as cystic fibrosis (CF), still face many challenges in developing efficacious gene therapy. The potential universal approach of gene replacement involves inserting a functional CFTR gene after generating DNA double strand breaks using gene editors such as CRISPR/Cas9. However, this strategy has not achieved clinical significance, as CRISPR/Cas9-mediated integration of CFTR is limited primarily by the infrequent activity of the homology-directed repair (HDR) pathway. To circumvent this limitation and improve CFTR transgene integration and expression, we explored a method of adding a second integration site, which we termed the dual-locus-targeting method. Using a helper-dependent adenoviral vector (HDAd)-delivered CRISPR/Cas9 system in porcine epithelial cells, we found that sequential delivery of two vectors, one targeting the CFTR locus and the other the genomic safe harbour site GGTA1, enhanced the integration efficiency of lacZ and CFTR donor genes to 16.5% and 3.4%, respectively. These results demonstrated a potential strategy to improve the efficacy of CFTR replacement for the development of a universal and permanent gene therapy treatment for CF lung disease. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=76 SRC="FIGDIR/small/731381v1_ufig1.gif" ALT="Figure 1"> View larger version (17K): org.highwire.dtl.DTLVardef@14c8583org.highwire.dtl.DTLVardef@d1862eorg.highwire.dtl.DTLVardef@1c0594eorg.highwire.dtl.DTLVardef@1271c10_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Investigation of Double-Stranded DNA Donors and CRISPR-Cas9 RNP for Universal Correction of Mutations Causing Cystic Fibrosis in Human Airway Cells
Vrishti Sinha, Paul George Ayoub, … Donald B. Kohn·bioRxiv·Sep 21, 2025
- Targeted replacement of full-length CFTR in human airway stem cells by CRISPR/Cas9 for pan-mutation correction in the endogenous locus
S. Vaidyanathan, R. Baik, … M. Porteus·bioRxiv·Feb 26, 2021
- Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site-Specific Integration of CFTR and Mutation-Agnostic Disease Rescue
Ruth A. Foley, Paul George Ayoub, … Steven John Jonas·Advanced Functional MaterialsPeer-reviewed·Jan 4, 2026
- DNA-PKcs Inhibition Improves Sequential Gene Insertion of the Full-Length CFTR cDNA in Airway Stem Cells
Jacob T. Stack, Rachael E. Rayner, … Sriram Vaidyanathan·Molecular Therapy — Nucleic AcidsPeer-reviewed·Sep 17, 2024
- A systemically delivered AAV-CFTR gene therapy for cystic fibrosis
Lindsey W. Plasschaert, Cian Stutz, … Amy Lin·bioRxiv·Mar 20, 2025
- Highly Efficient Repair of the ΔF508 Mutation in Airway Stem Cells of Cystic Fibrosis Patients with Functional Rescue of the Differentiated Epithelia
S. Vaidyanathan, A. A. Salahudeen, … M. H. Porteus·bioRxiv·Feb 26, 2019